Hormonal Contraception and Vaginal Health

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Oregon Clinical and Translational Research Institute
• Treatments: Desogestrel; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Etonogestrel; NuvaRing; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Female

• 18-35 years

• In general good health

• With regular menses (every 28-32 days)

• Seeking contraception and willing to use a hormonal method for at least 6 months

Exclusion Criteria:

• Current or recent (within the past 8 weeks) vaginitis or pelvic inflammatory disease

• History of recurrent vaginitis (> 2 episodes in one year, any type)

• Pregnancy

• Recent use of hormonal contraceptives

• Depot medroxyprogesterone: 6 months

• Progestin implants: 3 months

• Oral contraceptives: 3 months

• Hormone impregnated IUD: 3 months

• Contraindications to use of oral contraceptive pills or vaginal ring

• History of deep vein thrombosis

• Known coagulopathy or thrombophilia

• Unexplained vaginal bleeding

• Uncontrolled hypertension

• Diabetes with vascular changes

• Present or history of hepatic disease or liver tumors

• Migraines with neurologic changes

• Myocardial infection

• Pulmonary embolus

• Stroke

• Breast cancer

• Hypersensitivity or allergy to hormonal contraception

• Heavy Smoking ( ≥ 15 cigarettes per day)